Advertisement

Efficacy and Safety of Lapatinib and Trastuzumab for HER2-Positive Breast Cancer: a Systematic Review and Meta-Analysis of Randomised Controlled Trials

Based on the evidence from this study, the addition of lapatinib to trastuzumab can significantly improve pathological complete response rate, event-free survival, and overall survival with a tolerated toxicity in patients with HER2-positive breast cancer.

Efficacy and Safety of Lapatinib and Trastuzumab for HER2-Positive Breast Cancer: a Systematic Review and Meta-Analysis of Randomised Controlled Trials

 BMJ Open